Company intelligence / Profile preview
Sequella, Inc.
Rockville, Maryland, United Statessequella.com ↗
- Ownership
- Private
- Employees
- ~3
- Development stage
- Phase 2
01
Overview
Sequella has developed SQ109, a drug candidate for tuberculosis treatment that has progressed to clinical trials. They filed a second IND for SQ109 for treatment of Helicobacter pylori infections in 2010. The company has licensed rights to commercialize SQ109 for tuberculosis in Russia and neighboring Commonwealth of Independent States countries.
- Therapeutic areas
- Infectious Diseases
- Modalities
- Small molecules
- Industry
- Biotech
02
Drug pipeline
5 assets4 more assets in the full pipeline.
03
Partnerships
National Institute of Allergy and Infectious Diseases (NIAID)National Institutes of Health (NIH)Maxwell Biotech Venture Fund
Beyond the preview
Go deeper on Sequella, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Sequella, Inc..